Exelgyn

Mifepristone was originally developed by the French pharmaceutical company Roussel-Uclaf.

In 1997, after buying the remaining 43.5% of Roussel-Uclaf stock in early 1997,^[1] Hoechst AG announced the end of its manufacture and sale of Mifegyne

1997, Exelgyn S.A. was founded, a single-product company immune to antiabortion boycotts, whose CEO was former Roussel-Uclaf CEO Édouard Sakiz. Hoechst AG transferred all rights for medical uses of mifepristone (outside of the United States) to Exelgyn.^[2]

In 1999, Exelgyn won approval of Mifegyne in 11 additional countries.^[3] As of 2024, Exelgyn distributes mifepristone to 40 countries,^[4] but within the United States it is distributed by Danco Laboratories and GenBioPro.

• Official website